



Farmacia  
**HOSPITALARIA**

Órgano oficial de expresión científica de la Sociedad Española de Farmacia Hospitalaria

[www.elsevier.es/farmaciahospitalaria](http://www.elsevier.es/farmaciahospitalaria)



## [Translated article] The need for prolonged antiviral use to prevent recurrences of herpes simplex virus ocular disease: A systematic review

Laura Ruiz Sifre<sup>a</sup>, Sylvia Bort Martí<sup>b</sup>, Vicente Ruiz García<sup>c,\*</sup> and Ángeles Ruth Bort Martí<sup>d</sup>

<sup>a</sup> Facultad de Farmacia, Universidad de Valencia, Valencia, Spain

<sup>b</sup> HIPRA, Girona, Spain

<sup>c</sup> Unidad de Hospitalización a Domicilio, Hospital Universitari i Politècnic La Fe, Departamento de Salud Valencia La Fe, Valencia, Spain

<sup>d</sup> Servicio de Oftalmología, Hospital Universitari i Politècnic La Fe, Departamento de Salud Valencia La Fe, Valencia, Spain

### ARTICLE INFO

#### Article history:

Received 28 December 2024

Accepted 6 February 2025

Available online xxxx

#### Keywords:

Keratitis herpetic

Secondary prevention

Antiviral agents

Recurrence

Visual acuity

### A B S T R A C T

**Objective:** To evaluate in patients with a history of keratitis by herpes simplex virus, ocular recurrences, visual acuity, non-ocular recurrences, stromal keratitis and adverse effects after prolonged treatment with antiviral agents. Registered in Prospero CRD42024556228.

**Methods:** Systematic review of trials identified in CENTRAL, Embase, Medline, [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) and World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) ([www.who.int/ictip](http://www.who.int/ictip)). Trials of patients with a history of at least one episode of herpes simplex keratitis were included. Participants had to be free of active herpetic disease at the time of enrollment in the trial. Trials had to include oral and/or topical antiviral agents versus placebo or other antivirals, administered for at least 4 weeks. A data extraction was performed by pairs with risk of bias assessment for each trial using Cochrane Risk of Bias; GRADE was used to provide the certainty of evidence for each outcome.

**Results:** Four trials were found that included 1,017 patients. Antivirals in prolonged use protected from recurrences of ocular herpetic disease better than placebo (RR 0.56; 95% CI 0.45–0.70) NNT 6 (4–11); acyclovir was better than placebo in this same action (RR 0.59; 95% CI 0.46–0.74) NNT 8 (5–14), but not different from valacyclovir (RR 1.0; 95% CI 0.37–2.70) NNT not calculated. Prolonged use of antivirals also decreased recurrences of non-ocular herpetic disease (RR 0.56; 95% CI 0.44–0.71) NNT 6 (5–11) and recurrences with stromal keratitis (RR 0.55; 95% CI 0.35–0.85) NNT 17 (10–50). No data were found on visual acuity. Regarding adverse effects, there were no differences between interventions (RR 0.96; 95% CI 0.60–1.54) NNT not calculated. The certainty of evidence was high for ocular and non-ocular recurrences, and low for adverse effects, due to imprecision and inconsistency of the findings.

**Conclusions:** Prolonged use of antivirals protects from ocular, non-ocular recurrences and stromal keratitis safely. The effects on visual acuity are not known.

© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

### La necesidad de prolongar el uso de antivirales para prevenir recurrencias de la enfermedad ocular por virus de herpes simple. Revisión sistemática

### R E S U M E N

**Objetivo:** evaluar en pacientes con antecedentes de queratitis por el virus herpes simple las recurrencias oculares, agudeza visual, recurrencias no oculares, la queratitis estromal y los efectos adversos tras el tratamiento prolongado con agentes antivirales. Registrada en Prospero CRD42024556228.

**Método:** revisión sistemática de ensayos identificados en CENTRAL, Embase, Medline, [www.ClinicalTrials.gov](http://www.ClinicalTrials.gov) y World Health Organization (WHO) International Clinical Trials Registry Platform (ICTRP) ([www.who.int/ictip](http://www.who.int/ictip)). Se incluyeron ensayos de pacientes con antecedentes de al menos un episodio de queratitis por herpes simple. Los participantes debían estar libres de enfermedad herpética activa en el momento de inscribirse en el ensayo.

#### Palabras clave:

Queratitis herpética

Prevención secundaria

Agentes antivirales

Recurrencia

Agudeza visual

DOI of original article: <https://doi.org/10.1016/j.farma.2025.02.005>.

\* Corresponding author.

E-mail address: [vicenteruizgarcia@gmail.com](mailto:vicenteruizgarcia@gmail.com) (V. Ruiz García).

<https://doi.org/10.1016/j.farma.2025.03.019>

1130-6343/© 2025 The Author(s). Published by Elsevier España, S.L.U. on behalf of Sociedad Española de Farmacia Hospitalaria (S.E.F.H). This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Please cite this article as: Ruiz Sifre L, et al.. [Translated article] The need for prolonged antiviral use to prevent recurrences of herpes simplex virus ocular disease: A systematic review. Farmacia Hospitalaria. 2025. <https://doi.org/10.1016/j.farma.2025.03.019>

Los ensayos debían incluir agentes antivirales orales y tópicos versus placebo u otros antivirales, administrados durante al menos 4 semanas. Se realizó una extracción de datos por pares con evaluación de riesgo de sesgo para cada ensayo usando Riesgo de Sesgo de Cochrane; se usó GRADE para proporcionar la certeza de evidencia de cada resultado.

**Resultados:** se encontraron 4 ensayos que incluyeron a 1.017 pacientes. Los antivirales en uso prolongado protegieron de las recurrencias de la enfermedad herpética ocular mejor que el placebo (RR 0,56; IC 95% 0,45–0,70) NNT 6 (4–11); aciclovir fue mejor que el placebo en esta misma acción (RR 0,59; IC 95% 0,46–0,74) NNT 8 (5–14), pero no diferente de valaciclovir (RR 1,0; IC 95% 0,37–2,70) NNT no calculado. El uso prolongado de antivirales disminuyó también las recurrencias de enfermedad herpética no ocular (RR 0,56; IC 95% 0,44–0,71) NNT 6 (5–11) y de recurrencias con queratitis estromal (RR 0,55; IC 95% 0,35–0,85) NNT 17 (10–50). No se encontraron datos sobre agudeza visual. En cuanto a los efectos adversos, no hubo diferencias entre intervenciones (RR 0,96; IC 95% 0,60–1,54) NNT no calculado. La certeza de evidencia fue alta para las recurrencias oculares y no oculares, y baja para efectos adversos, por imprecisión e inconsistencia de los hallazgos.

**Conclusiones:** el uso prolongado de antivirales protege de recurrencias oculares, no oculares y queratitis estromal de forma segura. No se conocen los efectos sobre la agudeza visual.

© 2025 Los Autores. Publicado por Elsevier España, S.L.U. en nombre de Sociedad Española de Farmacia Hospitalaria (S.E.F.H). Este es un artículo Open Access bajo la licencia CC BY-NC-ND (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

## Introduction

Herpes simplex virus (HSV) is a leading cause of infection-related corneal opacification and loss of vision in the USA and other high-income countries<sup>1</sup>. Following initial primary exposure to ophthalmic HSV, latent infection is established, resulting in frequent asymptomatic ocular HSV recurrences.

Herpes simplex keratitis (HSK) is a corneal infection secondary to the reactivation of a latent HSV<sup>2</sup>. HSK is primarily caused by VHS-1, with VHS-2 being rarely the causative agent<sup>3</sup>. HSK recurrences are very frequent and may cause corneal opacification.<sup>4</sup> The estimated incidence/prevalence of HSK is 500,000 new cases reported in the USA annually and 1.54 million new cases reported worldwide, including 40,000 new cases of severe visual impairment or blindness<sup>5</sup>.

Complications of recurrent HSK primarily include corneal blindness secondary to scarring or perforation, and a dry eye<sup>6</sup>.

The management of recurrent HSK ranges from no active (antiviral) treatment, as episodes are self-limiting even when left untreated, through antiviral therapies that may relieve symptoms but not eliminate the infection ("lifelong latency")<sup>2</sup>. Oral antiviral agents include acyclovir, famciclovir and valaciclovir. Topical ophthalmic antivirals include trifluridine (most commonly prescribed in the USA), ganciclovir, and acyclovir (first-line treatment in Europe but not available in the USA).

A systematic review of the efficacy and safety of the antivirals currently available would help prevent one of the leading causes of blindness and improve the quality of life of patients. Guidelines recommend the prophylactic use of antiviral agents (oral, ophthalmic or combinations of the two) to prevent herpes recurrences<sup>7</sup>. However, these guidelines are obsolete and are based on the results of clinical trials, not on a systematic review.

The objective of this review is to determine whether long-term use of antiviral therapies in patients with a history of ocular HSV infection is effective in reducing ocular and extra-ocular HSV recurrences, preventing loss of vision, reducing stromal keratitis recurrences, and preventing the occurrence of adverse events (AEs), as compared to placebo or other medications (including other antivirals).

## Methods

The protocol for this systematic review and meta-analysis was prospectively registered to PROSPERO (CRD42024556228)<sup>8</sup>. Results are reported in accordance with PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-analyses) guidelines<sup>9</sup>.

## Types of studies

Our meta-analysis included randomized clinical trials involving patients with one or several episodes of ocular HSV infection in one or two eyes, without age- or sex-based differences. The first episode was not considered an ocular disease for recurrent HSV, but only the subsequent episode(s) of ocular HSV recurrence(s). Participants were required to be free of active herpetic disease before and at registration in the clinical trial. The clinical trials (CTs) were required to involve the use of oral or topical antiviral agents versus an oral or ophthalmic topical agent other than the ones administered in the intervention, placebo (oral or topical), and no active treatment. In the case of CTs with more than two intervention arms, the arms not relevant to our comparative study were excluded. Cross-sectional studies were excluded, as a critical event may occur long after the end of the intervention. Moreover, determining whether recurrence was prevented by the first or the second period of intervention (carry-over period) was not possible. The included CTs involved treatments with a minimum duration of 4 weeks and a minimum follow-up period of three months.

## Data collection

Cochrane's Database of Controlled Clinical Trials (CENTRAL) at Cochrane's Library (latest issue); Embase.com (from 1947 to June 1, 2024); Medline via PubMed (from 1948 to June 1, 2024); National Database of Ongoing Clinical Trials of the USA National Institutes of Health ClinicalTrials.gov ([www.ClinicalTrials.gov](http://www.ClinicalTrials.gov)) and the WHO International Clinical Trials Registry Platform ([www.who.int/ictpr](http://www.who.int/ictpr)). All records were searched until June 1, 2024.

To gather as much relevant evidence as possible, additional relevant articles were identified by manual inspection of reference lists from retrieved papers and systematic reviews.

## Search words

MESH descriptors and free text were used with the following Boolean combinations: [Keratitis, Herpetic], [Keratitis, Dendritic] [Herpes Simplex] [Eye Diseases] [Acyclovir] [Ganciclovir] [Valaciclovir] [Famciclovir]. [Randomized Controlled Trial]. The search strategies and filters used, along with the characteristics of studies (Annex 2), are included in the Supplementary Material (Annex 1).

### Study selection and data extraction

Potentially eligible studies were selected by two independent reviewers using Rayyan<sup>®</sup> software. Following title and abstract screening, eligible studies were selected for full-text reading by two independent reviewers. Data were peer reviewed and entered into a spreadsheet. Assessment of risk of bias was also performed. Discrepancies were resolved by an independent third reviewer.

### Primary outcomes

Primary outcomes included the proportion of participants with active recurrent HSV infection; decline (reduction) of the best-corrected visual acuity (BCVA), defined as mean differences in BCVA of 0.2LogMAR or 2 Snellen lines with respect to baseline status; and the proportion of participants with a BCVA decline >0.2LogMAR or two Snellen lines with respect to baseline status.

### Secondary outcomes

Proportion of participants with extra-ocular HSV recurrences including, but not limited to, genital and orofacial HSV infection; proportion of participants with ocular disease secondary to HSV recurrences who develop stromal keratitis; and frequency of AEs and serious AEs.

### Risk of bias in clinical trials

The risk of bias in the selected CTs was assessed using Cochrane's ROB1 tool, which includes random sequence generation; allocation concealment; blinding of participants and personnel; blinding of outcome assessors; incomplete outcome data; selective reporting, and other sources of bias<sup>10,11</sup>.

### Effect measures

The effect of the intervention on dichotomous variables was assessed using relative risk (RR) and the associated 95% confidence intervals (95%CI). The number needed to treat for an additional beneficial effect (NNTB) was calculated from the RR. The NNT was calculated using the  $NNT = 1/ACR * (1 - RR)$  formula, where ACT, also known as the baseline risk or risk for an AE, is the outcome of interest with the comparator intervention. To assess differences in continuous variables, differences between means with their 95% CI were estimated<sup>11</sup>. Estimators were calculated using Revman 5.4<sup>®</sup> software.

### Subgroup analysis

Subgroup analysis was conducted to identify potential sources of differences (where more than 10 CTs were available) in the effect of the intervention on primary outcomes based on the following factors:

- Duration of treatment, considering 6 months as short-term; 6–12 months as intermediate term; and 12 months as long-term treatment.
- Duration of follow-up for outcome analysis: considering 6 months as short-term; 6–12 months as intermediate term; and 12 months as long-term.
- Type of intervention, according to whether the intervention involved an oral antiviral agent alone; a topical ophthalmic antiviral agent alone, or a combination of the two.
- Dosage of the antiviral agent.

### Certainty of the reported evidence

The GRADE tool was used to assess the overall certainty of evidence<sup>12</sup>. Two authors of this review independently assessed the certainty of the evidence available, including the risk of bias in the CTs, imprecision, indirectness, inconsistency and potential publication bias.

### Summary table of outcomes

Tables were constructed to summarize the findings for each outcome. The tables included RR and NNT estimates for the pre-defined outcomes with their 95% CIs. The certainty of evidence based on the Overall Summary of Findings is also detailed in the tables<sup>13</sup>.

## Results

The meta-analysis included four CTs<sup>14–17</sup> involving a total of 1017 patients, with sample sizes ranging from 52<sup>15</sup> to 703<sup>14</sup> patients. The characteristics of the studies are detailed in the Annex to the Supplementary Material. All CTs reported effectiveness and AE data. The patients were free of active herpes infection at the start of the CT and had a history of one or several episodes of herpetic keratitis. No age limit was applied in this review. A systematic review<sup>18</sup> and 5 trials<sup>19–23</sup> were excluded, as they included patients with a previous keratoplasty. Appendix 1 summarizes the characteristics of the studies included. The search strategies used on each database are detailed in Appendix 2.

The studies were conducted in the USA, Italy and China and were published between 1994<sup>14</sup> and 2015<sup>16</sup>. The follow-up period ranged from 12 to 32 months<sup>16</sup>.

Table 1 contains the assessment of risk of bias in the CTs included. No competing interests were declared in any of the three studies<sup>15–17</sup>. Competing interests were declared in a study<sup>14</sup>, which was the study with the lowest risk of bias due to its design and sample size.

Fig. 2 contains efficacy and safety results. The GRADE certainty of evidence is detailed in Table 2.

### Primary endpoints

Three studies, including a total of 972 participants, assessed ocular HSV recurrence<sup>13,15,16</sup>. The incidence of ocular HSV recurrences

**Table 1**  
Risk of bias of the clinical trials included.

	a	b	c	d	e	f	g
Herpetic Eye Disease Study Group, 2000							
Miserochchi, 2007							
Wang, 2015							
Wu, 2002							

- (a) Random sequence generation (selection bias).  
(b) Allocation concealment (selection bias).  
(c) Blinding of participants and personnel (intervention bias).  
(d) Blinding of outcome assessor (detection bias).  
(e) Incomplete outcome data.  
(f) Selective outcome reporting.  
(g) Other sources of bias.

**Table 2**  
GRADE certainty of evidence.


Number of CTs (n)	ROB	Inc	Ind Evi	Imp	OC	n Antiv	n Plac	RR (95%CI)	MD (95%CI)	NNT	Cer
<i>Recurrences of herpetic keratitis: antivirals vs. placebo</i>											
3	Low	Low	Low	Low	Low	97/523	144/449	0.56 (0.45–0.70)	−0.16 (−0.23–0.09)	6 (4–11)	High
<i>Recurrences of herpetic keratitis: acyclovir vs. placebo</i>											
3	Low	Low	Low	Low	Low	87/465	131/422	−0.59 (0.46–0.74)	−0.13 (0.19–0.07)	8 (5–14)	High
<i>Acyclovir vs. valaciclovir</i>											
1	Low	Low	Low	Serious	Low	6/26	6/26	1.00 (0.37–2.7)	0.00 (−0.23–0.23)	Not estimated	Mod
<i>Extra-ocular recurrences</i>											
2	Low	Low	Low	Low	Low	80/405	139/394	0.56 (0.44–0.71)	−0.16 (−0.22–0.09)	6 (5–11)	High
<i>Stromal keratitis recurrences</i>											
2	Low	Low	Low	Low	Low	28/405	50/394	0.55 (0.35–0.85)	−0.06 (−0.10–0.02)	17 (10–50)	High
<i>All adverse events</i>											
4	Low	Mod	Low	Low	Low	31/549	27/468	0.96 (0.60–1.54)	0.01 (−0.02–0.04)	Not estimated	Low
<i>Serious adverse events</i>											
3	Low	Mod	Low	Moderate	Low	6/465	3/442	1.24 (0.31–4.88)	0.01 (−0.03–0.05)	Not estimated	Low

Cer: Certainty; Indirect Evidence; Imp: Imprecision; Inc.: Inconsistency; Mod: Moderate; OC: Other considerations; ROB: Risk of bias in clinical trials.

decreased in the antiviral group (RR 0.56; 95%CI 0.45–0.70;  $I^2 = 0\%$ ; NNT 6; 95%CI 4–11) (Fig. 1A). The certainty of evidence for this outcome was high. Of all antivirals, acyclovir was the most extensively studied, as its effects were assessed in three studies aggregately including 887 patients<sup>13,15,16</sup>. This agent also induced a reduction in ocular HSV recur-

rences (RR 0.59; 95%CI 0.46–0.74;  $I^2 = 0\%$ ; NNT 8; 95%CI 5–14), with a high certainty of evidence (Fig. 1B).

We only found a comparative study assessing two antivirals (acyclovir and valaciclovir)<sup>15</sup>, which included 52 patients. The certainty of evidence in this study was moderate (certainty was downgraded by




**Figure 1.** PRISMA flowchart.

one level due to imprecision). No significant differences were observed between the two antivirals in the reduction of ocular HSV recurrences (RR 1; 95%CI 0.37–2.70;  $I^2$  not applicable) (Fig. 1C).

The other pre-defined primary outcome was a decline in visual acuity, but this outcome was not reported in any study.


### Secondary endpoints

Acyclovir exerted protective effects against extra-ocular HSV recurrences, as compared to placebo, with a high certainty of evidence: two studies involving 799 participants<sup>14,17</sup>; RR 0.56; 95%CI 0.44–0.71;  $I^2$





#### Footnotes

- (1) Aciclovir  
(2) Ganciclovir




#### Footnotes

- (1) Para poder comparar aciclovir/placebo, el "n" y los eventos del grupo placebo se dividió por dos.



#### Footnotes

- (1) Aciclovir: 62 recurrencias orofaciales, 3 genitales, uno no definido y 5 en más de un sitio y Placebo: 111...



#### Risk of bias legend

- (A) Random sequence generation (selection bias)  
(B) Allocation concealment (selection bias)  
(C) Blinding of participants and personnel (performance bias)  
(D) Blinding of outcome assessment (detection bias)  
(E) Incomplete outcome data (attrition bias)  
(F) Selective reporting (reporting bias)  
(G) Other bias

### E

Figure 2. Forest plot of antiviral effectiveness.



= 0%; NNT 6 (95%CI 5–11) (Fig. 1D), with a high certainty of evidence. The low NNT observed suggests that this agent is very effective. Otherwise, with very few patients treated (5–10), recurrences will decrease, as compared to not treating the patients with antivirals.

As stromal keratitis is the most likely AE to cause a permanent loss of vision, studies were screened for this AE, and two studies including 799 participants were identified<sup>14,17</sup>; RR 0.55; 95%CI 0.35–0.85;  $I^2 = 0\%$ ; NNT 17; 95%CI 10–50 (Fig. 1E), with a high certainty of evidence.

Patients exhibited good tolerance to treatment. No differences were observed between groups in the occurrence of all AEs<sup>14–17</sup> (four studies including 1017 participants, RR 0.96; 95%CI 0.60–1.54;  $I^2 = 0\%$ , with a moderate certainty of evidence (imprecision and inconsistency caused two-level downgrading). No differences were observed either regarding the occurrence of AEs (three studies<sup>14,16,17</sup> with 907 participants, RR 1.24; 95%CI 0.31–4.88;  $I^2 = 0\%$ , with low certainty of evidence due to imprecision and inconsistency) (Fig. 2A and B, respectively). (See Fig. 3.)

An analysis of sensitivity for the primary outcome was performed (antivirals vs. placebo). Following the removal of the largest study<sup>11</sup>, a RR of 0.40 was obtained, with a 95%CI 0.27–0.58;  $I^2 = 0\%$ , which does not change the direction of effect and demonstrates the consistency of the analysis.

The limited number of studies included hindered subgroup analysis, and no tools could be used to detect publication bias.

## Discussion

### Comprehensiveness

The studies included did not report data for all the primary outcomes of this review.

### Certainty of evidence

The certainty of evidence was high for the outcome 'clinical effectiveness' and low for 'AEs'. Considering the risk of bias inherent to the design of CTs, the blinding limitations in three of the four studies did not result in downgrading, as this limitation did not affect the outcome in most variables. In the comparative study of acyclovir versus valaciclovir, imprecision caused certainty to be downgraded by one level. In the two safety outcomes, certainty was lowered two levels due to imprecision and inconsistency.

### Sensitivity analysis

Removal of the study with the largest sample and best design did not influence outcomes, as antivirals retained their protective effects against recurrences.




Figure 3. Forest Plot of safety.

## Concordance and discordance with other studies and reviews

A Cochrane systematic review published in 2016 was retrieved during the search process. This study assessed recurrences reported for acyclovir versus placebo in patients with keratoplasty<sup>18</sup>. The results of this review are consistent with the 2016 Cochrane review, which recommended the prophylactic use of antivirals to prevent recurrences in patients with keratoplasty.

## Clinical discussion

The evidence gathered in this review is not solid enough to conclusively establish the dosage and duration of antiviral treatments to prevent recurrences. However, as most studies included a follow-up period longer than one year, apparently, acyclovir (400 mg/12 h) can be safely administered, since it is the most extensively studied agent and was used for more than a year in all CTs.

On the other hand, further studies are needed to determine whether discontinuance of antiviral therapy is associated or not with an increased incidence of recurrences.

## Future research

Further clinical trials with different antivirals at different doses and follow-up periods are needed where visual acuity is also assessed.

The evidence currently available demonstrates that antivirals have protective effects against ocular (and extra-ocular) herpetic recurrences. This protective effect was confirmed for acyclovir and other antivirals (valaciclovir/ganciclovir).

The AEs related to the use of antivirals were similar to those reported in the placebo group.

## Current knowledge

Herpes simplex generally remains latent, thereby causing frequent recurrences. Herpetic keratitis is the leading cause of decline in visual acuity and blindness in developed countries.

Beyond management of the acute phase, prophylactic antiviral treatment is not administered on a routine basis.

## Contribution to the scientific literature

This original study is a thorough review of the evidence available on the prophylactic use of antivirals to prevent ocular herpetic recurrences.

This study reveals that long-term use of antivirals after the acute phase reduces the incidence of recurrences by a half.

Additional AEs were not identified in the patients treated. This finding is consistent with other studies in corneal transplant recipients.

## Assignment of rights

All authors assign the rights to Hospital Pharmacy.

## CRediT authorship contribution statement

**Laura Ruiz Sifre:** Writing – review & editing, Writing – original draft, Validation, Methodology, Formal analysis, Conceptualization. **Sylvia Bort Martí:** Writing – review & editing, Writing – original draft, Data curation, Conceptualization. **Vicente Ruiz García:** Writing – review & editing, Writing – original draft, Validation, Supervision, Formal analysis, Data curation, Conceptualization. **Ángeles Ruth Bort Martí:** Writing – review & editing, Writing – original draft, Validation, Methodology, Formal analysis, Conceptualization.

## Funding

The authors did not receive any funding for the preparation of this manuscript.

## Declaration of competing interest

The authors declare no conflicts of interest.

## Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.farma.2025.03.019>.

## References

- Austin A, Lietman T, Rose-Nussbaumer J. Update on the management of infectious keratitis. *Ophthalmology*. 2017;124:1678–89. doi:10.1016/j.ophtha.2017.05.012.
- Azher TN, Yin X-T, Tajfirouz D, Huang AJ, Stuart PM. Herpes simplex keratitis: challenges in diagnóstico and clinical management. *Clin Ophthalmol*. 2017;11:185–91. doi:10.2147/OPHT.S80475.
- Steiner I, Benninger F. Update on herpes virus infections of the nervous system. *Curr Neurol Neurosci Rep*. 2013;13:414. doi:10.1007/s11910-013-0414-8.
- Kalezic T, Mazen M, Kuklinski E, Asbell P. Herpetic eye disease study: lessons learned. *Curr Opin Ophthalmol*. 2018;29:340–6. doi:10.1097/ICU.0000000000000482.
- McCormick I, James C, Welton NJ, Mayaud P, Turner KME, Gottlieb SL, et al. Incidence of herpes simplex virus keratitis and other ocular disease: global review and estimates. *Ophthalmic Epidemiol*. 2022;29:353–62. doi:10.1080/09286586.2021.1962919.
- Tuli S, Gray M, Shah A. Surgical management of herpetic keratitis. *Curr Opin Ophthalmol*. 2018;29:347–54. doi:10.1097/ICU.0000000000000484.
- White ML, Chodosh J. Herpes simplex virus keratitis: a treatment guideline; 2014. [Accessed 27 Oct 2024]. Available at: <https://www.aao.org/assets/6564936e-9929-48b6-93cd-15872a1b388e/635732518522630000/hsv-keratitis-treatment-guideline-harvard.pdf>.
- Ruiz García V, Bort Martí A, Bort-Martí S, Ruiz Sifre L. Antiviral agents for preventing recurrent herpes simplex keratitis. PROSPERO. International prospective register of systematic review; 2024. [Accessed 26 Oct 2024]. Available at: [https://www.crd.york.ac.uk/prospero/display\\_record.php?RecordID=556228](https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=556228).
- Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. *PLoS Med*. 2021;18:e1003583. doi:10.1371/journal.pmed.1003583.
- Higgins JPT, Savović J, Page MJ, Elbers RG, Sterne JAC. Chapter 8: Assessing risk of bias in a randomized trial [last updated October 2019]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. *Cochrane handbook for systematic reviews of interventions* version 6.5. Cochrane; 2024. [Accessed 27 Oct 2024]. Available at: [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- Higgins JPT, Li T, Deeks JJ. Chapter 6: Choosing effect measures and computing estimates of effect [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. *Cochrane handbook for systematic reviews of interventions* version 6.5. Cochrane; 2024. [Accessed 27 Oct 2024]. Available at: <https://training.cochrane.org/handbook/current/chapter-06>.
- Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. *BMJ*. 2008;336:924–6. doi:10.1136/bmj.39489.470347.AD.
- Schünemann HJ, Higgins JPT, Vist GE, Glasziou P, Akl EA, Skoetz N, et al. Chapter 14: Completing ‘Summary of findings’ tables and grading the certainty of the evidence [last updated August 2023]. In: Higgins JPT, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editors. *Cochrane handbook for systematic reviews of interventions* version 6.5. Cochrane; 2024. [Accessed 27 Oct 2024]. Available at: [www.training.cochrane.org/handbook](http://www.training.cochrane.org/handbook).
- Wilhelmus KR, Beck RW, Moke PS, Dawson CR, Barron BA, Jones DB, et al. Acyclovir for the prevention of recurrent herpes simplex virus eye disease. *N Engl J Med*. 1998;339:300–6. doi:10.1056/NEJM199807303390503.
- Miserocchi E, Modorati G, Galli L, Rama P. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study. *Am J Ophthalmol*. 2007;144:547–51. doi:10.1016/j.ajo.2007.06.001.
- Wang X, Wang L, Wu N, Ma X, Xu J. Clinical efficacy of oral ganciclovir for prophylaxis and treatment of recurrent herpes simplex keratitis. *Chin Med J (Engl)*. 2015;128:46–50. doi:10.4103/0366-6999.147808.
- Wu X, Chen X. Acyclovir for the treatment and prevention of recurrent infectious herpes simplex keratitis. *Chin Med J (Engl)*. 2002;115:1569–72.
- Bhatt UK, Abdul Karim M, Prydal JI, Maharajan SV, Fares U. Oral antivirals for preventing recurrent herpes simplex keratitis in people with corneal grafts. *Cochrane Database Syst Rev*. 2016;2016. doi:10.1002/14651858.CD007824.pub2.

19. Akova YA, Onat M, Duman S. Efficacy of low-dose and long-term oral acyclovir therapy after penetrating keratoplasty for herpes simplex heratitis. *Ocul Immunol Inflamm.* 1999;7:51–60. doi:[10.1076/ocii.7.1.51.8113](https://doi.org/10.1076/ocii.7.1.51.8113).
20. Barney N, Foster C. A prospective randomized trial of oral acyclovir after penetrating keratoplasty for herpes simplex keratitis. *Cornea.* 1994;13:232–6. doi:[10.1097/00003226-199405000-00007](https://doi.org/10.1097/00003226-199405000-00007).
21. Foster CS, Barney NP. Systemic acyclovir and penetrating keratoplasty for herpes simplex keratitis. *Doc Ophthalmol Adv Ophthalmol.* 1992;80:363–9. doi:[10.1007/BF00154385](https://doi.org/10.1007/BF00154385).
22. van Rooij J, Rijneveld W, Remeijer L, Völker-Dieben H, Eggink C, Geerards A, et al. Effect of oral acyclovir after penetrating keratoplasty for herpetic keratitis: a placebo-controlled multicenter trial. *Ophthalmology.* 2003;110:1916–9. doi:[10.1016/S0161-6420\(03\)00798-X](https://doi.org/10.1016/S0161-6420(03)00798-X).
23. Mayer K, Reinhard T, Reis A, Voiculescu A, Sundmacher R. Synergistic antiherpetic effect of acyclovir and mycophenolate mofetil following keratoplasty in patients with herpetic eye disease: first results of a randomized pilot study. *Graefes Arch Clin Exp Ophthalmol.* 2003;241:1051–4. doi:[10.1007/s00417-003-0724-7](https://doi.org/10.1007/s00417-003-0724-7).